Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 567 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Trialling a new way to boost CAR T-cell therapy June 23, 2021 What’s at the Root of Ovarian Cancer? New Study May Have... April 24, 2025 Free Rides to Screening Appointments Thanks to Woman Who Lost Mother... May 16, 2019 Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves... February 15, 2022 Load more HOT NEWS Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... Turning the Life Sciences Vision into reality EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers
